Altogether, these results suggest that, based on the proband's genetic and functional characteristics, the antidepressant drug fluoxetine may be repurposed for the treatment of focal epilepsy caused by gain-of-function variants in <i>KCNT1</i>. Here, KCNT1 is linked to focal epilepsy.